Literature DB >> 17877762

High mobility group protein HMGA1 inhibits retinoblastoma protein-mediated cellular G0 arrest.

Yasuaki Ueda1, Sugiko Watanabe, Shuchin Tei, Noriko Saitoh, Jun-Ichi Kuratsu, Mitsuyoshi Nakao.   

Abstract

Retinoblastoma protein (RB) acts as a tumor suppressor in many tissue types, by promoting cell arrest via E2F-mediated transcriptional repression. In addition to the aberrant forms of the RB gene found in different types of cancers, many viral oncoproteins including the simian virus 40 large T antigen target RB. However, cellular factors that inhibit RB function remain to be elucidated. Here, we report that RB interacts with the high mobility group protein A1 (HMGA1), a-non-histone architectural chromatin factor that is frequently overexpressed in cancer cells. HMGA1 binds the small pocket domain of RB, and competes with HDAC1. Subsequently, overexpression of HMGA1 abolishes the inhibitory effect of RB on E2F-activated transcription from the cyclin E promoter. Under serum starvation, T98G cells had been previously shown to be arrested in the G0 phase in an RB-mediated manner. The G0 phase was characterized by growth arrest and low levels of transcription, together with the hypophosphorylation of RB and the downregulation of HMGA1. In contrast, such serum-depleted G0 arrest was abrogated in T98G cells overexpressing HMGA1. The overexpressed HMGA1 was found to form complexes with cellular RB, suggesting that downregulation of HMGA1 is required for G0 arrest. There were no phenotypic changes in HMGA1-expressing T98G cells in the presence of serum, but the persistent expression of HMGA1 under serum starvation caused various nuclear abnormalities, which were similarly induced in T antigen-expressing T98G cells. Our present findings indicate that overexpression of HMGA1 disturbs RB-mediated cell arrest, suggesting a negative control of RB by HMGA1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17877762     DOI: 10.1111/j.1349-7006.2007.00608.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  12 in total

1.  Histone Citrullination Represses MicroRNA Expression, Resulting in Increased Oncogene mRNAs in Somatolactotrope Cells.

Authors:  Stanley B DeVore; Coleman H Young; Guangyuan Li; Anitha Sundararajan; Thiruvarangan Ramaraj; Joann Mudge; Faye Schilkey; Aaron Muth; Paul R Thompson; Brian D Cherrington
Journal:  Mol Cell Biol       Date:  2018-09-14       Impact factor: 4.272

2.  High mobility group A1 protein acts as a new target of Notch1 signaling and regulates cell proliferation in T leukemia cells.

Authors:  Yang Xi; Yu-Sang Li; He-Bin Tang
Journal:  Mol Cell Biochem       Date:  2012-11-16       Impact factor: 3.396

Review 3.  pRb, a local chromatin organizer with global possibilities.

Authors:  Michelle S Longworth; Nicholas J Dyson
Journal:  Chromosoma       Date:  2009-08-28       Impact factor: 4.316

Review 4.  Interplay between HMGA and TP53 in cell cycle control along tumor progression.

Authors:  Nathalia Meireles Da Costa; Antonio Palumbo; Marco De Martino; Alfredo Fusco; Luis Felipe Ribeiro Pinto; Luiz Eurico Nasciutti
Journal:  Cell Mol Life Sci       Date:  2020-09-12       Impact factor: 9.261

5.  HMGA1 is induced by Wnt/beta-catenin pathway and maintains cell proliferation in gastric cancer.

Authors:  Shin-ichi Akaboshi; Sugiko Watanabe; Yuko Hino; Yoko Sekita; Yang Xi; Kimi Araki; Ken-ichi Yamamura; Masanobu Oshima; Takaaki Ito; Hideo Baba; Mitsuyoshi Nakao
Journal:  Am J Pathol       Date:  2009-09-03       Impact factor: 4.307

6.  HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis.

Authors:  Andrew Schuldenfrei; Amy Belton; Jeanne Kowalski; C Conover Talbot; Francescopaolo Di Cello; Weijie Poh; Hua-Ling Tsai; Sandeep N Shah; Tait H Huso; David L Huso; Linda M S Resar
Journal:  BMC Genomics       Date:  2011-11-04       Impact factor: 3.969

7.  HMGA1 exacerbates tumor growth through regulating the cell cycle and accelerates migration/invasion via targeting miR-221/222 in cervical cancer.

Authors:  Fangfang Fu; Tian Wang; Zhangying Wu; Yourong Feng; Wenwen Wang; Su Zhou; Xiangyi Ma; Shixuan Wang
Journal:  Cell Death Dis       Date:  2018-05-22       Impact factor: 8.469

8.  miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer.

Authors:  Evita Maria Lindholm; Miriam Ragle Aure; Mads Haugland Haugen; Kristine Kleivi Sahlberg; Vessela N Kristensen; Daniel Nebdal; Anne-Lise Børresen-Dale; Ole Christian Lingjaerde; Olav Engebraaten
Journal:  Mol Oncol       Date:  2019-08-28       Impact factor: 6.603

Review 9.  HMGA1 Is a Potential Driver of Preeclampsia Pathogenesis by Interference with Extravillous Trophoblasts Invasion.

Authors:  Keiichi Matsubara; Yuko Matsubara; Yuka Uchikura; Katsuko Takagi; Akiko Yano; Takashi Sugiyama
Journal:  Biomolecules       Date:  2021-05-31

10.  A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness.

Authors:  Silvia Pegoraro; Gloria Ros; Yari Ciani; Riccardo Sgarra; Silvano Piazza; Guidalberto Manfioletti
Journal:  Oncotarget       Date:  2015-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.